Formulation Development
Alzheon Advances Next-Gen Pipeline With First Patient Dosed in ALZ-507 Study
Alzheon, Inc. recently announced the dosing of the first cohort of human volunteer subjects in a Phase 1 single and multiple ascending dose clinical trial of…
Cereno Scientific Reports Robust Safety & Tolerability in Long‑Term CS1 Pulmonary Arterial Hypertension Study
Cereno Scientific provides additional context on the safety and tolerability data from up to 12 months of treatment from the Expanded Access Program (EAP) with…
ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology
ANI Pharmaceuticals, Inc. recently announced publication of the results from the NEW DAY clinical trial involving ILUVIEN (fluocinolone acetonide intravitreal implant), 0.19 mg (ILUVIEN) for…
FORE Biotherapeutics Receives Breakthrough Therapy Designation for Plixorafenib
FORE Biotherapeutics, a registration-stage company dedicated to developing targeted therapies to treat patients with cancer, today announced that the U.S. Food and Drug Administration (FDA)…
Adragos Pharma Finalizes the Acquisition of Commercial-Scale, Sterile Fill-Finish Manufacturing Site From Sanofi
Adragos Pharma recently announced it completed the acquisition of a commercial-scale sterile fill-finish facility in Maisons-Alfort, France, from Sanofi. The Maisons-Alfort site is one of…
Cyclerion Therapeutics & Korsana Biosciences Announce Merger Agreement
Cyclerion Therapeutics, Inc. and Korsana Biosciences, Inc. recently announced they have entered into a definitive merger agreement for an all-stock transaction. Upon completion of the…
Amprion Grows Global Footprint With Australian Partnership & Expanded Research Collaborations
Amprion recently announced a series of strategic milestones that underscore the company’s accelerating growth, expanding international footprint, and continued commitment to advancing earlier and more accurate…
Samsung Biologics Completes Acquisition of GSK’s Manufacturing Facility
Samsung Biologics recently announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company’s first manufacturing presence in…
Symeres & Ambagon Therapeutics Collaborate on Molecular Glue Research in Colorectal Cancer
Symeres has recently partnered with Ambagon Therapeutics, a pre-clinical biotechnology company, to explore a new class of small molecules, known as molecular glues, for potential…
ImmuneOncia Therapeutics & Lonza Collaborate to Manufacture a PD-L1 Antibody Targeting Immuno-Oncology
ImmuneOncia Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on immuno-oncology, and Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), announced today…
Vetter Recognized as 2026 CDMO Leadership Awards Winner
Vetter receives recognition as CDMO of the year in the category “Finished Dose” of the 2026 CDMO Leadership Awards. The award honors the company for…
Quotient Therapeutics Announces Collaboration With Merck to Discover Novel Drug Targets in Inflammatory Bowel Disease Using Somatic Genomics Platform Technology
Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, today announced that it has entered a multi-year research collaboration agreement with Merck, known…
Karyopharm’s Phase 3 in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction
Karyopharm Therapeutics Inc. recently reported topline results from its Phase 3 SENTRY trial, a randomized, double-blind, placebo-controlled trial of 60 mg selinexor in combination with…
ImmuneBridge Announces New Partnership Focus, Investment & CEO
ImmuneBridge recently announced it will make its platform available to partners – ranging from small biotech startups to established pharmaceutical companies. Therapeutic co-development partners will…
Nanexa Demonstrates Feasibility of Quarterly Semaglutide Dosing with PharmaShell
Nanexa AB recently announced highly promising new results from its long‑acting semaglutide program, developed using the company’s proprietary PharmaShell drug delivery platform. Building on the…
Basecamp Research Launches Trillion Gene Atlas to Scale AI-Designed Therapeutics
Basecamp Research recently announced the launch of the Trillion Gene Atlas, a landmark scientific initiative to generate and model biological data at the trillion-gene scale.…
One-carbon Therapeutics Signs Strategic Collaboration With Tempus to Advance Molecular Insights & Enable Precision Oncology Development of TH9619
One-carbon Therapeutics recently announced a strategic collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine.…
Green Light for First-in-Human Trial of KMCAR T-cell Therapy in Multiple Myeloma
HaemaLogiX Ltd and Peter MacCallum Cancer Centre (Peter Mac) are delighted to announce the achievement of a landmark regulatory milestone: receipt of Clinical Trial Approval…
Lonza & Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO
-Extended agreement will expand manufacturing capacity at Lonza Houston (US) to support growing demand for Genetix’s ZYNTEGLO (betibeglogene autotemcel), the only FDA-approved gene therapy for…
Centauri Therapeutics Granted FDA QIDP Status for CTX-187 Treatment of Gram-Negative Bacterial Infections
Centauri Therapeutics Limited recently announced the its lead clinical candidate in the ABX-01 program, CTX-187, has received Qualified Infectious Disease Product (QIDP) designation from the…
